
Biocon Biologics, an Indian pharmaceutical company, has announced the launch of a biosimilar version of AbbVie's blockbuster rheumatoid arthritis drug, Humira, in the United States. Biosimilars are close alternatives to complex biologic drugs, offering competition and potentially lower prices. The launch of Biocon Biologics' biosimilar, branded as Hulio, adds to the growing list of biosimilars introduced by other drugmakers. Hulio will be available at a list price below that of Humira, providing a more affordable treatment option for patients. AbbVie expects competition to impact Humira sales in 2023, following its record-breaking sales in 2022.
Like
Save
Share